Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 614 of 5804
-
HER2+ breast cancer patients may finally get a treatment holiday
Disease control OngoingThis study is being done to see if anti-HER2 treatment be safely stopped in patients with HER2-positive metastatic breast cancer (MBC) that have had exceptional response to treatment. Exceptional response" is considered as cancer progression being controlled for three years or mo…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Can a short course of hepatitis c drugs before kidney transplant prevent infection?
Disease control Recruiting nowThis study is being done to find out the best time to start medication for Hepatitis C Virus (HCV) in HCV-negative recipients of HCV-positive (HCV D+/R-) kidney transplants. Participants will be randomized into one of two groups: Arm 1 - Prophylaxis: This group will start the HC…
Phase: NA • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug combo shows promise for tough lung cancers
Disease control OngoingThe purpose of this study is to evaluate the safety, tolerability and objective response rate of SKB264 as combination with therapy in subjects with advanced or metastatic non-small cell lung cancer.
Phase: PHASE2 • Sponsor: Klus Pharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Could a Two-Drug combo curb cocaine cravings? new study says maybe
Disease control CompletedThis is an 8-week, double-blind, randomized placebo-controlled trial of the efficacy of a combination of extended-release naltrexone (XR-NTX) and extended-release buprenorphine (XR-BUP) compared to matched placebo injections (PBO-Inj) for the treatment of cocaine use disorder (CU…
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New pill targets Hard-to-Treat cancers: early trial recruits 554 patients
Disease control Recruiting nowBDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced ma…
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a CO2-Removal device save lives in severe COPD attacks?
Disease control TerminatedThe aim of the study is to determine which standard of care strategy will best benefit very severe Acute Exacerbation (AE) of Chronic Obstructive Pulmonary Disease (COPD), single versus reinforced with ECCO2R and assess the respective efficacy and the safety. Very severe AE of CO…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New pill may keep endometrial cancer at bay longer
Disease control OngoingThe purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors versi…
Phase: PHASE3 • Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
AI reads heart traces to find silent liver danger
Diagnosis CompletedThe overall objectives of this study are to determine the effectiveness of ACE 2.0 model in early detection of advanced liver fibrosis, and to determine the acceptance and barriers for use of an AI-enabled algorithm for prediction of liver disease in primary care.
Phase: NA • Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 07:51 UTC
-
Engineered immune cells take on Hard-to-Treat cancers in early trial
Disease control OngoingThis is a Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarci…
Phase: PHASE1 • Sponsor: Legend Biotech USA Inc • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for kids with tough tumors: drug combo trial launches
Disease control Recruiting nowThis trial is a multi-center, non-randomized, open-label Phase I/II study evaluating the feasibility and efficacy of vincristine, irinotecan, temozolomide, and atezolizumab in children with relapsed/refractory solid tumors.
Phase: PHASE1, PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Texting program aims to help smokers with HIV kick the habit
Disease control ENROLLING_BY_INVITATIONThe intersection of smoking and HIV/AIDS poses a serious public health threat in Vietnam. Vietnam is dealing with these two challenges with parallel rather than integrated plans. Using a computer-tailored texting intervention, study investigators seek to promote the use of an und…
Phase: NA • Sponsor: University of Massachusetts, Worcester • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Stroke showdown: drug plus procedure vs. procedure alone for basilar artery blockage
Disease control CompletedCurrently, both intravenous thrombolysis (IVT) followed by endovascular treatment (EVT) and EVT alone are widely used for the treatment of acute ischemic stroke (AIS) caused by basilar artery occlusion (BAO) (AIS-BAO), but no direct comparison of their efficacy and safety was rep…
Phase: NA • Sponsor: Sichuan Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New drug zanubrutinib takes on kidney disease in major trial
Disease control OngoingThe primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to evaluate the efficacy of zanubrutinib compared with tacrolimus as measured by complete remission rate, in participants with primary …
Phase: PHASE2, PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New drug spesolimab shows promise for painful skin condition
Disease control CompletedThis study is open to adults with moderate to severe hidradenitis suppurativa (HS). The purpose of this study is to find out whether a medicine called spesolimab helps people with HS. People who have previously taken specific medicines such as immunosuppressive biologics other th…
Phase: PHASE2, PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Heart bypass showdown: does using more arteries help women?
Disease control Recruiting nowThe central hypothesis of ROMA:Women is that the use of multiple arterial grafting (MAG) will improve clinical outcomes and quality of life (QOL) compared to single arterial grafting (SAG). The specific aims of ROMA:Women are: Aim 1: Determine the impact of MAG vs SAG on major …
Phase: NA • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New device aims to save kidneys and lives in the ICU
Disease control Recruiting nowThis randomized, controlled, pivotal study is intended to determine whether up to ten sequential 24-hour treatments with the Selective Cytopheretic Device (SCD) will improve survival in patients with Acute Kidney Injury (AKI) requiring continuous kidney replacement therapy (CKRT)…
Phase: NA • Sponsor: SeaStar Medical • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New TB drug cocktail aims to shorten treatment
Disease control Recruiting nowThis is a phase 2B/C, open label platform study that will compare the efficacy, safety of experimental regimens with a standard control regimen in participants with newly diagnosed, drug sensitive pulmonary tuberculosis. In stage 1, participants will be randomly allocated to the…
Phase: PHASE2 • Sponsor: Michael Hoelscher • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Needle vs. IV: which isatuximab method works best for myeloma?
Disease control CompletedThe trial aims to demonstrate the non-inferiority of subcutaneous to intravenous isatuximab administration in transplant-eligible patients with newly diagnosed multiple myeloma.
Phase: PHASE3 • Sponsor: University of Heidelberg Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New CAR T-Cell therapy targets tough lymphomas
Disease control Recruiting nowTo find the highest tolerable dose of JV-213 (a type of autologous CAR T cell therapy) that can be given to patients who have B-cell lymphoma that is relapsed or refractory.
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
One shot for two viruses? moderna tests combo mRNA vaccine
⭐️ VACCINE ⭐️ CompletedThe study is divided into 2 parts: Part 1 and Part 2. The purpose of Part 1 of this study is to generate sufficient safety, reactogenicity, and immunogenicity data to enable selection of an mRNA-1083 vaccine composition and dose level to evaluate in a subsequent Phase 3 clinical …
Phase: PHASE1, PHASE2 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:06 UTC